

Luigi Celio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/885244/publications.pdf>

Version: 2024-02-01

74
papers

2,194
citations

361045

20
h-index

253896

43
g-index

74
all docs

74
docs citations

74
times ranked

2170
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2000, 18, 2234-2244.	0.8	302
2	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. , 1999, 86, 858-865.		249
3	Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women. <i>Journal of Clinical Oncology</i> , 2005, 23, 2155-2161.	0.8	200
4	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 53-66.	2.0	137
5	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. <i>Cancer</i> , 1993, 72, 3099-3105.	2.0	121
6	Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. <i>Annals of Oncology</i> , 2002, 13, 614-621.	0.6	103
7	2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. <i>Supportive Care in Cancer</i> , 2017, 25, 277-288.	1.0	103
8	Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. <i>Supportive Care in Cancer</i> , 2011, 19, 1217-1225.	1.0	96
9	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1. <i>European Journal of Cancer</i> , 1999, 35, 208-213.	1.3	65
10	Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer. <i>Annals of Oncology</i> , 2003, 14, 1543-1548.	0.6	51
11	Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone. <i>Annals of Surgical Oncology</i> , 2009, 16, 2985-2993.	0.7	50
12	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2007, 18, 1810-1816.	0.6	34
13	The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 63, 261-267.	1.2	33
14	Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. <i>Annals of Oncology</i> , 2000, 11, 1017-1022.	0.6	31
15	Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1393-1395.	0.9	27
16	Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. <i>British Journal of Cancer</i> , 1994, 70, 145-150.	2.9	26
17	Prospective evaluation of estrogen receptor- β^2 in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. <i>Endocrine-Related Cancer</i> , 2004, 11, 761-770.	1.6	25
18	Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. <i>Supportive Care in Cancer</i> , 2013, 21, 565-573.	1.0	25

#	ARTICLE	IF	CITATIONS
19	Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. <i>BMC Cancer</i> , 2019, 19, 1268.	1.1	24
20	One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. <i>Oncologist</i> , 2019, 24, 1593-1600.	1.9	21
21	Salvage Treatment After Interferon α -2a in Advanced Neuroendocrine Tumors. <i>Acta Oncologica</i> , 1993, 32, 245-250.	0.8	20
22	Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. <i>Oncologist</i> , 2021, 26, e1073-e1082.	1.9	20
23	Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients. <i>Oncology</i> , 1994, 51, 262-269.	0.9	19
24	Pemetrexed in gastric cancer: Clinical experience and future perspectives. <i>Seminars in Oncology</i> , 2002, 29, 63-68.	0.8	19
25	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. <i>Annals of Oncology</i> , 2009, 20, 1062-1067.	0.6	18
26	Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial. <i>The Journal of Supportive Oncology</i> , 2012, 10, 65-71.	2.3	18
27	Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. <i>Core Evidence</i> , 2015, 10, 75.	4.7	18
28	Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 661-680.	1.3	18
29	Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review. <i>Tumori</i> , 2006, 92, 72-75.	0.6	17
30	Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. <i>Patient Preference and Adherence</i> , 2013, 7, 391.	0.8	17
31	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 146, 3495-3503.	2.3	17
32	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 439-449.	1.6	16
33	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019, 19, e306-e318.	1.1	16
34	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , 2021, 26, e1854-e1861.	1.9	16
35	Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. <i>Cancer Treatment Reviews</i> , 1993, 19, 31-36.	3.4	15
36	Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. <i>British Journal of Cancer</i> , 1995, 71, 1111-1114.	2.9	15

#	ARTICLE	IF	CITATIONS
37	Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994, 30, 127-132.	1.1	14
38	Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. <i>BMJ Open</i> , 2017, 7, e015645.	0.8	13
39	Clinical Update on Palonosetron in the Management of Chemotherapy-Induced Nausea and Vomiting. <i>Tumori</i> , 2008, 94, 447-452.	0.6	12
40	Novel Non-Steroidal Aromatase Inhibitors: Are There New Perspectives in the Treatment of Breast Cancer?. <i>Tumori</i> , 1996, 82, 417-422.	0.6	11
41	Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002, 80, 411-418.	1.2	11
42	Feasibility Study of Biweekly Capecitabine, Oxaliplatin, and Irinotecan in Patients with Untreated Advanced Gastric Cancer. <i>Tumori</i> , 2009, 95, 43-47.	0.6	9
43	Research on Chemotherapy-Induced Nausea: Back to the Past for an Unmet Need?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1376-1377.	0.8	9
44	Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer-and lymphokine-activated-killer-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 1992, 34, 272-278.	2.0	8
45	Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT. <i>Tumori</i> , 1999, 85, 6-11.	0.6	8
46	Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. <i>Future Oncology</i> , 2014, 10, 2569-2578.	1.1	8
47	Formestane as Treatment of Advanced Breast Cancer in Elderly Women. <i>Tumori</i> , 1994, 80, 433-437.	0.6	7
48	The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 75, 65-73.	1.2	7
49	Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials. <i>Future Oncology</i> , 2013, 9, 1451-1458.	1.1	7
50	Is the Dexamethasone-Sparing Strategy Ready For Cisplatin? Too Early For an Answer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2741-2742.	0.8	7
51	Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. <i>Tumori</i> , 2008, 94, 447-52.	0.6	7
52	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020, 20, 232.	1.1	6
53	Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study. <i>Tumori</i> , 2019, 105, 253-258.	0.6	5
54	Ovarian Ablation for Premenopausal Early-Stage Breast Cancer: An Update. <i>Tumori</i> , 2000, 86, 191-194.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Should clinicians always administer dexamethasone beyond 24h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. <i>Supportive Care in Cancer</i> , 2016, 24, 1025-1034.	1.0	4
56	Everyday palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the Rete Ematologica Pugliese. <i>Cancer Medicine</i> , 2020, 9, 170-178.	1.3	4
57	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020, 12, 617.	1.7	4
58	Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. <i>Tumori</i> , 2012, 98, 279-86.	0.6	4
59	Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?. <i>International Journal of Oncology</i> , 2003, 22, 1081.	1.4	3
60	Palonosetron: An Evidence-Based Choice in Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy. <i>Tumori</i> , 2012, 98, 279-286.	0.6	3
61	Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer Analysis of a Phase II Trial. <i>Oncology</i> , 2013, 84, 371-377.	0.9	3
62	Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2185-2186.	0.8	3
63	Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1267-1277.	0.9	3
64	Adjuvant Oophorectomy versus CMF in Premenopausal Node-Positive Breast Cancer: Long-Term Results of an Experience at the Milan Cancer Institute. <i>Tumori</i> , 2000, 86, 258-259.	0.6	2
65	Measurement of Thrombin Generation Is a Positive Predictive Biomarker of Venous Thromboembolism (VTE) in Metastatic Cancer Patients Enrolled in the Hypercan Study. <i>Blood</i> , 2015, 126, 654-654.	0.6	2
66	Hypercoagulation Screening As a Marker of Thrombosis and Poor Disease Prognosis in Cancer Patients: The Hypercan Prospective Study. <i>Blood</i> , 2014, 124, 586-586.	0.6	2
67	A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15637-e15637.	0.8	1
68	Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron. <i>Cancer Management and Research</i> , 2009, 1, 89-97.	0.9	1
69	Acute confusional state with fatal outcome in a cancer patient. <i>Neurological Sciences</i> , 2004, 24, 424-425.	0.9	0
70	Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy. , 2016, , 135-156.		0
71	A new standard prophylaxis for emesis caused by cisplatin?. <i>Lancet Oncology</i> , The, 2020, 21, e128.	5.1	0
72	Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21688-e21688.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Pre-Chemotherapy Levels of Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Metastatic Cancer Patients from the Hypercan Study. Blood, 2018, 132, 3795-3795.	0.6	0
74	Abstract 1390: Molecular characterization of circulating tumor cells in cholangiocarcinoma patients: A new tool for treatment management. , 2019, , .		0